Melanoma Risk in 12,205 Kidney Transplant Recipients Receiving Calcineurin Inhibitor-Based Immunosuppression: A Nationwide Analysis of Polish National Health Fund Data (2010-2022).

Cancers (Basel) · 2026 · PMC12939293 · PMID 41749895

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The minimal differences observed between the TAC and CsA groups did not reach statistical significance, indicating that the choice between these two calcineurin inhibitors does not appear to have a substantial impact on melanoma incidence over the analyzed follow-up period.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.